-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NXxT39UT8821F7iLY8o4G2bACm4dT1KAWaxl/SkjyvLumbmgQC7KM6tt8tfXNXKK fGqWU8Tta/FIbOwfmKq5tA== 0000950142-07-001111.txt : 20070511 0000950142-07-001111.hdr.sgml : 20070511 20070511171459 ACCESSION NUMBER: 0000950142-07-001111 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20070511 DATE AS OF CHANGE: 20070511 GROUP MEMBERS: FRANK H. PEARL GROUP MEMBERS: GEORGE SOROS GROUP MEMBERS: PERSEUS BIOTECH FUND PARTNERS, LLC GROUP MEMBERS: PERSEUS-SOROS BIOPHARMACEUTICAL FUND, L.P. GROUP MEMBERS: PERSEUS-SOROS PARTNERS, LLC GROUP MEMBERS: PERSEUSPUR, LLC GROUP MEMBERS: SFM AH LLC GROUP MEMBERS: SFM PARTICIPATION, L.P. GROUP MEMBERS: SOROS FUND MANAGEMENT LLC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: REPLIDYNE INC CENTRAL INDEX KEY: 0001180145 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841568247 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-81890 FILM NUMBER: 07843279 BUSINESS ADDRESS: STREET 1: 1450 INFINITE DRIVE CITY: LOUISVILLE STATE: CO ZIP: 80027 BUSINESS PHONE: 303-665-3450 MAIL ADDRESS: STREET 1: 1450 INFINITE DRIVE CITY: LOUISVILLE STATE: CO ZIP: 80027 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: PERSEUS SOROS BIOPHARMACEUTICAL FUND LP CENTRAL INDEX KEY: 0001111408 IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: ARMY & NAVY CLUB BLDG STREET 2: 1627 I ST NW STE 610 CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: (212) 651-6389 MAIL ADDRESS: STREET 1: 888 SEVENTH AVE STREET 2: 30TH FL CITY: NEW YORK STATE: NY ZIP: 10106 SC 13G/A 1 sc13ga1_replidyne.txt AMENDMENT NO. 1 =============================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* REPLIDYNE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 76028W107 (CUSIP Number) Amendment to the Schedule 13G Previously Filed for the DECEMBER 31, 2006 Event Date (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [_] Rule 13d-1(c) [X] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the reminder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). =============================================================================== CUSIP NO. 76028W107 Schedule 13G Page 2 of 20 - -------------------------------------------------------------------------------- 1. Name of Reporting Person Perseus-Soros BioPharmaceutical Fund, LP S.S. or I.R.S. Identifica- tion No. of Above Person - -------------------------------------------------------------------------------- 2. Check the Appropriate Box (a) [_] if a Member of a Group (b) [X] - -------------------------------------------------------------------------------- 3. S.E.C. Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization Delaware - -------------------------------------------------------------------------------- Number of Shares (5) Sole Voting Power 1,487,808 Beneficially (6) Shared Voting Power 0 Owned by Each (7) Sole Dispositive Power 1,487,808 Reporting Person (8) Shared Dispositive Power 0 - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,487,808 - -------------------------------------------------------------------------------- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares [_] - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row 9 5.5% - -------------------------------------------------------------------------------- 12. Type of Reporting Person PN - -------------------------------------------------------------------------------- CUSIP NO. 76028W107 Schedule 13G Page 3 of 20 - -------------------------------------------------------------------------------- 1. Name of Reporting Person Perseus-Soros Partners, LLC S.S. or I.R.S. Identifica- tion No. of Above Person - -------------------------------------------------------------------------------- 2. Check the Appropriate Box (a) [_] if a Member of a Group (b) [X] - -------------------------------------------------------------------------------- 3. S.E.C. Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization Delaware - -------------------------------------------------------------------------------- Number of Shares (5) Sole Voting Power 1,487,808 Beneficially (6) Shared Voting Power 0 Owned by Each (7) Sole Dispositive Power 1,487,808 Reporting Person (8) Shared Dispositive Power 0 - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,487,808 - -------------------------------------------------------------------------------- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares [_] - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row 9 5.5% - -------------------------------------------------------------------------------- 12. Type of Reporting Person OO - -------------------------------------------------------------------------------- CUSIP NO. 76028W107 Schedule 13G Page 4 of 20 - -------------------------------------------------------------------------------- 1. Name of Reporting Person Perseus BioTech Fund Partners, LLC S.S. or I.R.S. Identifica- tion No. of Above Person - -------------------------------------------------------------------------------- 2. Check the Appropriate Box (a) [_] if a Member of a Group (b) [X] - -------------------------------------------------------------------------------- 3. S.E.C. Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization Delaware - -------------------------------------------------------------------------------- Number of Shares (5) Sole Voting Power 0 Beneficially (6) Shared Voting Power 1,487,808 Owned by Each (7) Sole Dispositive Power 0 Reporting Person (8) Shared Dispositive Power 1,487,808 - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,487,808 - -------------------------------------------------------------------------------- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares [_] - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row 9 5.5% - -------------------------------------------------------------------------------- 12. Type of Reporting Person OO - -------------------------------------------------------------------------------- CUSIP NO. 76028W107 Schedule 13G Page 5 of 20 - -------------------------------------------------------------------------------- 1. Name of Reporting Person SFM Participation, L.P. S.S. or I.R.S. Identifica- tion No. of Above Person - -------------------------------------------------------------------------------- 2. Check the Appropriate Box (a) [_] if a Member of a Group (b) [X] - -------------------------------------------------------------------------------- 3. S.E.C. Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization Delaware - -------------------------------------------------------------------------------- Number of Shares (5) Sole Voting Power 0 Beneficially (6) Shared Voting Power 1,487,808 Owned by Each (7) Sole Dispositive Power 0 Reporting Person (8) Shared Dispositive Power 1,487,808 - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,487,808 - -------------------------------------------------------------------------------- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares [_] - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row 9 5.5% - -------------------------------------------------------------------------------- 12. Type of Reporting Person PN - -------------------------------------------------------------------------------- CUSIP NO. 76028W107 Schedule 13G Page 6 of 20 - -------------------------------------------------------------------------------- 1. Name of Reporting Person SFM AH LLC S.S. or I.R.S. Identifica- tion No. of Above Person - -------------------------------------------------------------------------------- 2. Check the Appropriate Box (a) [_] if a Member of a Group (b) [X] - -------------------------------------------------------------------------------- 3. S.E.C. Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization Delaware - -------------------------------------------------------------------------------- Number of Shares (5) Sole Voting Power 0 Beneficially (6) Shared Voting Power 1,487,808 Owned by Each (7) Sole Dispositive Power 0 Reporting Person (8) Shared Dispositive Power 1,487,808 - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,487,808 - -------------------------------------------------------------------------------- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares [_] - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row 9 5.5% - -------------------------------------------------------------------------------- 12. Type of Reporting Person OO - -------------------------------------------------------------------------------- CUSIP NO. 76028W107 Schedule 13G Page 7 of 20 - -------------------------------------------------------------------------------- 1. Name of Reporting Person Perseuspur, LLC S.S. or I.R.S. Identifica- tion No. of Above Person - -------------------------------------------------------------------------------- 2. Check the Appropriate Box (a) [_] if a Member of a Group (b) [X] - -------------------------------------------------------------------------------- 3. S.E.C. Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization Delaware - -------------------------------------------------------------------------------- Number of Shares (5) Sole Voting Power 0 Beneficially (6) Shared Voting Power 1,487,808 Owned by Each (7) Sole Dispositive Power 0 Reporting Person (8) Shared Dispositive Power 1,487,808 - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,487,808 - -------------------------------------------------------------------------------- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares [_] - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row 9 5.5% - -------------------------------------------------------------------------------- 12. Type of Reporting Person OO - -------------------------------------------------------------------------------- CUSIP NO. 76028W107 Schedule 13G Page 8 of 20 - -------------------------------------------------------------------------------- 1. Name of Reporting Person Frank H. Pearl S.S. or I.R.S. Identifica- (in the capacity described herein) tion No. of Above Person - -------------------------------------------------------------------------------- 2. Check the Appropriate Box (a) [_] if a Member of a Group (b) [X] - -------------------------------------------------------------------------------- 3. S.E.C. Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization United States - -------------------------------------------------------------------------------- Number of Shares (5) Sole Voting Power 0 Beneficially (6) Shared Voting Power 1,504,121* Owned by Each (7) Sole Dispositive Power 0 Reporting Person (8) Shared Dispositive Power 1,504,121* - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,504,121* - -------------------------------------------------------------------------------- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares [_] - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row 9 5.6%* - -------------------------------------------------------------------------------- 12. Type of Reporting Person IN - -------------------------------------------------------------------------------- * This amount includes 16,313 shares of common stock issuable upon the exercise of stock options issued to Christopher D. Earl, a director of the Company and a senior advisor to Perseus-Soros BioPharmaceutical Fund, LP. The stock options are held for the benefit of an entity controlled by affiliates of the Perseus-Soros BioPharmaceutical Fund, LP. CUSIP NO. 76028W107 Schedule 13G Page 9 of 20 - -------------------------------------------------------------------------------- 1. Name of Reporting Person George Soros S.S. or I.R.S. Identifica- (in the capacity described herein) tion No. of Above Person - -------------------------------------------------------------------------------- 2. Check the Appropriate Box (a) [_] if a Member of a Group (b) [X] - -------------------------------------------------------------------------------- 3. S.E.C. Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization United States - -------------------------------------------------------------------------------- Number of Shares (5) Sole Voting Power 0 Beneficially (6) Shared Voting Power 1,504,121* Owned by Each (7) Sole Dispositive Power 0 Reporting Person (8) Shared Dispositive Power 1,504,121* - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,504,121* - -------------------------------------------------------------------------------- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares [_] - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row 9 5.6%* - -------------------------------------------------------------------------------- 12. Type of Reporting Person IA - -------------------------------------------------------------------------------- * This amount includes 16,313 shares of common stock issuable upon the exercise of stock options issued to Christopher D. Earl, a director of the Company and a senior advisor to Perseus-Soros BioPharmaceutical Fund, LP. The stock options are held for the benefit of an entity controlled by affiliates of the Perseus-Soros BioPharmaceutical Fund, LP. CUSIP NO. 76028W107 Schedule 13G Page 10 of 20 - -------------------------------------------------------------------------------- 1. Name of Reporting Person Soros Fund Management LLC S.S. or I.R.S. Identifica- tion No. of Above Person - -------------------------------------------------------------------------------- 2. Check the Appropriate Box (a) [_] if a Member of a Group (b) [X] - -------------------------------------------------------------------------------- 3. S.E.C. Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization Delaware - -------------------------------------------------------------------------------- Number of Shares (5) Sole Voting Power 0 Beneficially (6) Shared Voting Power 1,504,121* Owned by Each (7) Sole Dispositive Power 0 Reporting Person (8) Shared Dispositive Power 1,504,121* - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,504,121* - -------------------------------------------------------------------------------- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares [_] - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row 9 5.6%* - -------------------------------------------------------------------------------- 12. Type of Reporting Person OO; IA - -------------------------------------------------------------------------------- * This amount includes 16,313 shares of common stock issuable upon the exercise of stock options issued to Christopher D. Earl, a director of the Company and a senior advisor to Perseus-Soros BioPharmaceutical Fund, LP. The stock options are held for the benefit of an entity controlled by affiliates of the Perseus-Soros BioPharmaceutical Fund, LP. CUSIP NO. 76028W107 Schedule 13G Page 11 of 20 EXPLANATORY NOTE: This Amendment No. 1 is being filed to correct the number of shares of Common Stock (as defined below) each of the Reporting Persons may be deemed to beneficially own, as originally reported in the Reporting Persons initial 13G filing, filed with the Securities and Exchange Commission on February 14, 2007 (the "Initial 13G"). The Initial 13G inadvertently omitted 119,426 shares of Common Stock owned by Perseus-Soros BioPharmaceutical Fund, LP. Each of the other Reporting Persons may also be deemed to beneficially own such shares. Item 1. (a) NAME OF ISSUER Replidyne, Inc. (the "Company"). (b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES 1450 Infinite Drive Louisville, CO 80027 Item 2. (a) NAMES OF PERSONS FILING This Statement is being filed on behalf of each of the following persons (collectively, the "Reporting Persons") (i) Perseus-Soros BioPharmaceutical Fund, LP, a Delaware limited partnership ("Perseus-Soros"); (ii) Perseus-Soros Partners, LLC, a Delaware limited liability company ("PSP GP" and general partner of Perseus-Soros); (iii) Perseus BioTech Fund Partners, LLC, a Delaware limited liability company ("PBFP Partners" and managing member of PSP GP); (iv) SFM Participation, L.P., a Delaware limited partnership ("SFM Participation" and managing member of PSP GP); (v) SFM AH LLC, a Delaware limited liability company ("SFM AH" and general partner of SFM Participation); (vi) Perseuspur, LLC, a Delaware limited liability company ("Perseuspur" and managing member of PBFP Partners); (vii) Mr. Frank H. Pearl ("Mr. Pearl" and sole member of Perseuspur); (viii) Mr. George Soros ("Mr. Soros" and Chairman of SFM LLC); and (ix) Soros Fund Management LLC, a Delaware limited liability company ("SFM LLC" and the sole managing member of SFM AH). CUSIP NO. 76028W107 Schedule 13G Page 12 of 20 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE The address of the principal business offices of (i) Perseus-Soros and (ii) PSP, GP is 888 Seventh Avenue, 30th Floor, New York, NY 10106. The address of the principal business offices of (i) PBFP Partners, (ii) Perseuspur and (iii) Mr. Pearl is 2099 Pennsylvania Ave., N.W., Suite 900, Washington, D.C. 20006. The address of the principal business offices of (i) SFM Participation, (ii) SFM AH, (iii) SFM LLC and (iv) Mr. Soros is 888 Seventh Avenue, 33rd Floor, New York, NY 10106. (c) CITIZENSHIP (i) Perseus-Soros - a Delaware limited partnership (ii) PSP GP - a Delaware limited liability company (iii) PBFP Partners - a Delaware limited liability company (iv) SFM Participation - a Delaware limited partnership (v) SFM AH - a Delaware limited liability company (vi) Perseuspur - Delaware limited liability company (vii) Mr. Pearl - United States (viii) Mr. Soros - United States (ix) SFM LLC - a Delaware limited liability company (d) TITLE OF CLASS OF SECURITIES Common Stock, par value $0.001 per share (the "Common Stock" or "Shares") (e) CUSIP NUMBER 76028W107 Information contained herein concerning SFM Participation, SFM AH, SFM LLC and Mr. Soros has been provided by SFM LLC. Perseus-Soros, PSP GP, PBFP Partners, Perseuspur and Mr. Pearl assume no responsibility for such information. Information contained herein concerning PBFP Partners, Perseuspur and Mr. Pearl has been provided by each such Reporting Person. Perseus-Soros, PSP GP, SFM Participation, SFM AH, SFM LLC and Mr. Soros assume no responsibility for such information. CUSIP NO. 76028W107 Schedule 13G Page 13 of 20 Item 3. This statement is not being filed pursuant to either Rule 13d-1(b) or 13d-2(b) or (c). Item 4. OWNERSHIP. (a) AMOUNT BENEFICIALLY OWNED: Each of the Reporting Persons other than Mr. Soros, Mr. Pearl and SFM LLC may be deemed to beneficially own 1,487,808 Shares. Each of Mr. Soros, Mr. Pearl and SFM LLC may be deemed to beneficially own an aggregate of 1,504,121 Shares, including 16,313 shares of common stock issuable upon the exercise of stock options. The stock options are held for the benefit of an entity controlled by affiliates of the Perseus-Soros BioPharmaceutical Fund, LP. (b) PERCENTAGE OWNED: Based on calculations made in accordance with Rule 13d-3(d), and there being 27,010,506 Shares outstanding as of April 26, 2007, each of the Reporting Persons, other than Mr. Soros, Mr. Pearl and SFM LLC, may be deemed to beneficially own approximately 5.5% of the outstanding Common Stock. Based on the same calculations, Mr. Soros, Mr. Pearl and SFM LLC may be deemed to beneficially own 5.6% of the outstanding common stock. (c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS: (i) Each of Perseus-Soros and PSP GP may be deemed to have sole power to direct the voting and disposition of the 1,487,808 Shares beneficially owned by Perseus-Soros. (ii) By virtue of the relationships between and among the Reporting Persons as described in Item 2, each of: (a) PBFP Partners, Perseuspur, SFM Participation and SFM AH may be deemed to share the power to direct the voting and disposition of 1,487,808 Shares beneficially owned by Perseus-Soros and (b) each of Mr. Soros, Mr. Pearl and SFM LLC may be deemed to share the power to direct the voting and disposition of the 1,487,808 Shares beneficially owned by Perseus-Soros, and the 16,313 Shares issuable upon the exercise of stock options. The stock options are held for the benefit of an entity controlled by affiliates of the Perseus-Soros BioPharmaceutical Fund, LP. Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS Not applicable. CUSIP NO. 76028W107 Schedule 13G Page 14 of 20 Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON The partners of Perseus-Soros have the right to participate in the receipt of dividends from, or proceeds from the sale of, the securities held for the account of Perseus-Soros in accordance with their ownership interests in Perseus-Soros. Item 7. IDENTIFICATION AND CLASSIFICATION OF SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY Not applicable. Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP Not applicable. Item 9. NOTICE OF DISSOLUTION OF GROUP Not applicable. Item 10. CERTIFICATION Not applicable. [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] CUSIP NO. 76028W107 Schedule 13G Page 15 of 20 SIGNATURES After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. Dated as of May 11, 2007 PERSEUS-SOROS BIOPHARMACEUTICAL FUND, LP By: Perseus-Soros Partners, LLC General Partner By: SFM Participation, L.P. Managing Member By: SFM AH LLC General Partner By: Soros Fund Management LLC Managing Member By: /s/ Jodye M. Anzalotta -------------------------------------- Name: Jodye M. Anzalotta Title: Assistant General Counsel CUSIP NO. 76028W107 Schedule 13G Page 16 of 20 PERSEUS-SOROS PARTNERS, LLC By: SFM Participation, L.P. Managing Member By: SFM AH LLC General Partner By: Soros Fund Management LLC Managing Member By: /s/ Jodye M. Anzalotta -------------------------------------- Name: Jodye M. Anzalotta Title: Assistant General Counsel PERSEUS BIOTECH FUND PARTNERS, LLC By: Perseuspur, LLC Member By: /s/ Kenneth M. Socha --------------------------------------- Name: Kenneth M. Socha Title: Senior Managing Director CUSIP NO. 76028W107 Schedule 13G Page 17 of 20 SFM PARTICIPATION, L.P. By: SFM AH LLC General Partner By: Soros Fund Management LLC Managing Member By: /s/ Jodye M. Anzalotta -------------------------------------- Name: Jodye M. Anzalotta Title: Assistant General Counsel SFM AH LLC By: Soros Fund Management LLC Managing Member By: /s/ Jodye M. Anzalotta -------------------------------------- Name: Jodye M. Anzalotta Title: Assistant General Counsel PERSEUSPUR, LLC By: /s/ Kenneth M. Socha --------------------------------------- Name: Kenneth M. Socha Title: Senior Managing Director CUSIP NO. 76028W107 Schedule 13G Page 18 of 20 MR. FRANK H. PEARL By: /s/ Kenneth M. Socha --------------------------------------- Name: Kenneth M. Socha Title: Attorney-in-Fact MR. GEORGE SOROS By: /s/ Jodye M. Anzalotta ---------------------------------------- Name: Jodye M. Anzalotta Title: Attorney-in-Fact SOROS FUND MANAGEMENT LLC By: /s/ Jodye M. Anzalotta -------------------------------------- Name: Jodye M. Anzalotta Title: Assistant General Counsel CUSIP NO. 76028W107 Schedule 13G Page 19 of 20 EXHIBIT INDEX ------------- Exhibit 1. Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (previously filed). Exhibit 2. Power of Attorney, dated June 16, 2005 appointing each of Armando T. Belly, Jodye Anzalotta, Maryann Canfield, Jay Schoenfarber and Robert Soros as Attorney-In-Fact for George Soros (previously filed). Exhibit 3. Power of Attorney, dated May 9, 2007, appointing Kenneth M. Socha and Rona Kennedy as Attorney-in-Fact for Frank H. Pearl. CUSIP NO. 76028W107 Schedule 13G Page 20 of 20 EXHIBIT 3 --------- POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that I, FRANK H. PEARL, hereby make, constitute and appoint each of Kenneth M. Socha and Rona Kennedy, each of them acting singly, as my agent and attorney-in-fact for the purpose of executing in my name, (a) in my personal capacity or (b) in my capacity as Chairman of, member of or in other capacities with Perseus, L.L.C. ("PERSEUS") and each of its affiliates or entities advised by me or Perseus, all documents, certificates, instruments, statements, filings and agreements ("DOCUMENTS") to be filed with or delivered to any foreign or domestic governmental or regulatory body or required or requested by any other person or entity pursuant to any legal or regulatory requirement relating to the acquisition, ownership, management or disposition of securities, futures contracts, or other investments, and any other documents relating or ancillary thereto, including, but not limited to, all documents relating to filings with the Commodities Futures Trading Commission and National Futures Association, the United States Securities and Exchange Commission (the "SEC") pursuant to the Commodities Exchange Act and the Securities Act of 1933 or the Securities Exchange Act of 1934 (the "Act") and the rules and regulations promulgated thereunder, including all documents relating to the beneficial ownership of securities required to be filed with the SEC pursuant to Section 13(d) or Section 16(a) of the Act and information statements on Form 13F required to be filed with the SEC pursuant to Section 13(f) of the Act. All past acts of either attorney-in-fact in furtherance of the foregoing are hereby ratified and confirmed. This power of attorney shall be valid from the date hereof until revoked by me. The Power of Attorney dated as of April 9, 2003 is hereby revoked by me effective as of the date hereof. IN WITNESS WHEREOF, I have executed this instrument as of the 9th day of May, 2007. /s/ Frank H. Pearl --------------------------- FRANK H. PEARL -----END PRIVACY-ENHANCED MESSAGE-----